Last reviewed · How we verify
The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer
The goal of this clinical research study is to find the highest tolerable dose of Avandamet that can be given in combination with exemestane to patients who are obese and postmenopausal with hormone-receptive-positive breast cancer that has spread to other parts of the body.
Details
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 25 |
| Start date | 2009-07 |
| Completion | 2012-08 |
Conditions
- Breast Cancer
Interventions
- Exemestane
- Avandamet
Primary outcomes
- Dose-limiting toxicity (DLT) — Day 1 of each cycle
Countries
United States